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1. Construction of tagged proteins library 
A library of fluorescently tagged proteins was constructed in non-small cell lung 
carcinoma cell line (H1299) in a two stage process. In both stages a fluorescent reporter 
was integrated into the genome via Central Dogma tagging (CD-tagging) (1-4).  
The first stage was carried out in order to produce a parental clone in which the nucleus is 
colored brighter than the cytoplasm and the cytoplasm is colored brighter than the 
background of the image. To achieve this, a red fluorescent protein, mCherry (5), was 
introduced in two rounds of CD-tagging. In the first round, clone H7a, expressing tagged 
protein XRCC5 localized to the nucleus, was selected. In the second round (carried out 
on the previously selected clone H7a), clone H7 expressing tagged DAP1 localized to the 
whole intracellular domain was selected. Following these two steps, a parental clone 
expressing two mCherry endogenously tagged proteins (XRCC5 and DAP1), stained in 
the cytoplasm and brighter in the nucleus was obtained. We find that the cell-cell 
variability of the red fluorescence in this clone is much smaller than the variability in 
clones generated in preliminary experiments by transfection with mCherry. This reduced 
variability was crucial for reliable image analysis of cell movies. 
The second stage in the generation of the library was to use CD-tagging in order to tag 
different proteins with a second color eYFP or Venus (6) within the parental clone H7 
(H1299-cherry). The CD-tagging protocol used in all rounds of library construction is 
described in detail by Sigal et al. (4). Briefly, a fluorescent protein (FP), flanked by splice 
acceptor and donor sequences was integrated into the genome as an artificial exon via 
retroviral vectors (U5000, U5001, U5002), each containing FP in one of 3 reading frames. 
Cells positive for relevant FP fluorescence were sorted using flow cytometry into 384 
well plates and expanded into cell clones. Tagged protein identities were determined by 
3’RACE, using a nested PCR reaction that amplified the section between the FP and the 
polyA tail of the mRNA of the host gene. The PCR product was sequenced directly and 
aligned to the genome. Our library of CD-tagged proteins is detailed at 
www.dynamicproteomics.net.  
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2. Long period time-lapse microscopy 
Time-lapse movies were obtained (at 20x magnification) as described by Sigal et al. (7) 
with an automated, incubated (including humidity and CO2 control) Leica DMIRE2 
inverted fluorescence microscope and an ORCA ER cooled CCD camera (Hamamatsu 
Photonics). The system was controlled by ImagePro5 Plus (Media Cybernetics) software 
which integrated time-lapse acquisition, stage movement, and software based auto-focus. 
During the experiment, cells were grown and visualized in 12-well coverslip bottom 
plates (MatTek) coated with 10µM fibronectin (Sigma). For each well, time lapse movies 
were obtained at four fields of view. Each movie was taken at a time resolution of 20 
minutes and was filmed for at least three days (over 200 time points). Each time point 
included three images- phase contrast, red and yellow fluorescence.  
 
3. Drug Materials 
Camptothecin (C9911 Sigma), was dissolved in DMSO (Dimethyl sulphoxide hybri-max), 
(SIGMA, D2650) to achieve a stock solution of 10mM. In each experiment, the drug was 
diluted to 10µM in a transparent growth medium (RPMI, 1% PenStrep, 10%FCS, w/o 
riboflavin, w/o phenol red, Biological Industries, Kibbutz Beit Haemek, Israel). Growth 
medium (2ml) was replaced by the diluted drug (2ml) under the microscope. The same 
procedure was carried for the following drugs: Etoposide (E1383 Sigma), dissolved to a 
stock of 10mM and diluted to 40µM and for Cisplatinum (P4394 Sigma) dissolved to 
100mM and diluted to 80µM. The stock solution for ActD (A1410 Sigma) was 1mg/ml 
and was diluted to 1µg/ml. The stock solution for Irinotecan was 10mM and was diluted 
to 250 µM in growth medium.  
 
4. Image analysis of time lapse movies 
We used a custom written image analysis tool developed using the Matlab image 
processing toolbox environment (Mathworks, Natick, MA). The main steps include; 
image correction, segmentation, tracking of the cells and automated identification of cell 
phenotypes (mitosis and cell death). 
Image background correction (flat field correction and background subtraction) was 
carried out as previously described (7). No significant bleaching was observed (on 
average less than 3% over the duration of the experiment). 
Cell and nuclei segmentation was based on the red fluorescent images – all clones in the 
library showed similar distribution of red fluorescence – bright in the cytoplasm and 
significantly brighter in the nucleus. The main steps of the segmentation process are:  1) 
Differentiation between cells and background by a global image threshold using Otsu's 
method (1); 2) Segmentation of neighboring cells by applying the seeded watershed 
segmentation algorithm. Seeds were obtained by smoothening the red intensity image and 
usage of bright nuclei as cell seeds (by identifying local maxima) – one seed per cell; 3) 
Nuclei segmentation following cell segmentation; each cell was independently stretched 
between zero and one and a fixed threshold was used to differentiate between the 
cytoplasm and the nucleus; 4) Tracking of cells was performed by analyzing the movie 
from end to start and linking each segmented cell to the cell in the previous image with 
the closest centroid.  
 
 
 4
5. Automated cell death and mitosis identification 
The automated cell death identification algorithm utilized the morphological changes 
correlated with dying cells: rounding followed by blebbing and an explosion of the outer 
membrane or its collapse (for example see Supporting movie 1). We constructed an 
artificial neural network (ANN) algorithm that can identify each one of these 
morphological patters similar to the method previously described in (8). Briefly, we 
constructed two sets of images: The first contained 400 cell images in different stages of 
cell death and the second contained 400 live cell images. For each image we computed a 
collection of high-level image texture features. An example of such a feature is a measure 
of object roundness, which is relevant due to the rounding that typically occurs prior to 
cell death. This process transforms each image into a multi dimensional vector of features. 
Based on these features we train an ANN classifier in order to distinguish between live 
and dead cells resulting in a 96% sensitivity and specificity on a previously unseen test 
set.  
We found that the dynamics of cell death measured by this algorithm follow closely the 
dynamics obtained by a standard neutral red assay (described below) on the cells (Fig. 
S3). The advantages of this algorithm is that it requires no external chemicals, and it 
allows direct count of the number of cells showing the correlates of death rather than a 
proxy (e.g. population average of ATP, membrane permeability or staining of organelles). 
Furthermore, the direct cell monitoring approach allows a high temporal resolution (every 
20 minutes for over 48 hours), which is usually not feasible using the alternative 
approaches. 
Cell division is identified by monitoring the temporal protein profile of cells and 
searching for sharp decreases in their protein content, which occur after divisions. These 
events are further filtered using morphology based considerations (using a similar 
framework as the one used for cell death) to improve detection accuracy. 
 
6. Neutral red assay: 
Cells were plated into 96 well plates at 1000 cells/well in normal growth conditions 
(37
o
C and 8% CO2). A day later drugs were added to the cells at the appropriate 
concentrations. Cell survival was determined by neutral red (NR) (Fluka Chemie, Buchs, 
cat #72210, Switzerland) accumulation as described (9, 10), and in the following way: 
growth medium was removed and neutral red reagent (4mg/ml, diluted to 1:100 in growth 
medium) was added for an incubation of 40 min at 37
o
C. After 40 minutes, the neutral 
red reagent was removed from the cells and fixation buffer (1% CaCl2, 0.5% 
Formaldehyde) was added at 150µl/well. Subsequently, the fixation buffer was removed 
and extraction buffer (1% Glacial Acetic Acid, 50% Ethanol) was added at 100µl/well. 
The plate was shaked vigorously and read in an ELISA plate reader (BIO-RAD Model 
680 Microplate Reader). After subtraction of assay blanks, net optical density (570 nm) 
was computed as the average value of triplicate determinations. The NR levels in 
response to CPT are shown in Fig. S3B. Cell survival was calculated as the percentage of 
the dye accumulated in the treated vs. untreated controls. 
 
7. Protein dynamics clustering 
The five average population dynamics profiles depicted in Fig. 2 were generated in the 
following manner: The levels of each protein were smoothed using a median filter and 
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linearly scaled between -1 and 1. The distance between every pair of proteins was 
measured in terms of Pearson correlation and clustering was performed using a k-means 
algorithm (reproducibility of results using different seeds is > 99%). To choose the 
number of clusters we optimized over the average silhouette score (11), which measures 
the dissimilarity of a protein to its assigned cluster compared to other clusters.  
 
 
8. Gene Ontology (GO) enrichment analysis 
To systematically search for functions, processes and localizations common to proteins 
that show similar dynamics we performed a GO (12) enrichment analysis procedure. We 
devised a distance measure that uses both the protein amount and its localization changes 
through time. Formally, each protein i is represented by two vectors, ci and ni, describing 
the amount of protein in the nucleus and cytoplasm respectively in 141 sequential time 
points each.  
The distance between each pair of proteins i and j was computed using the following 
formulas: 
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D1 is one minus the Pearson correlation between the total amounts of two proteins scaled 
between 0 and 1. D2 is the normalized Euclidian distance between two vectors that depict 
the protein localization at each time point. Notice that at a given time t, 
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range from 0 to 1 corresponding to a cytoplasmic and nuclear localization respectively. 
Dtot is the weighted sum of the protein amount and protein localization distances where 
w1 + w2 = 1 (we used w1 = 0.5 and w2 =0.5). The larger w2 is, the more emphasis is put 
on localization and consequentially the GO terms that were identified (see next 
paragraph) were more related to Cellular Compartments terms. 
The GO enrichment procedure was performed as following: For each protein we 
generated a list containing all other proteins ranked according to their distance. Each 
protein can be thought of as a cluster center and all the other proteins are ranked 
according to their distance from that center. We wanted to find whether a subset of 
proteins that show similar dynamics, i.e. reside near the cluster center, also share a 
common GO term. To this end we used a flexible cutoff version of the Hyper Geometric 
score termed mHG (13). This analysis was done using GORILLA software [http://cbl-
gorilla.cs.technion.ac.il/]. 
 
9. Quantification of nucleolar translocations 
To detect translocation events between the nucleoli and the nucleoplasm, we followed a 
three step procedure. First we focused on a subgroup of clones that showed initial nuclear 
localization of the YFP tagged protein (i.e. pixels of the nucleus were the source of over 
1
1 ( , )
( , )
2
i i j j
Corr n c n c
D i j
− + +
=
 6
50 % of the total intensity). Then, for each of the selected clones we calculated the ratio 
of fluorescence intensity between the top and bottom ten percent pixels in individual 
nuclei and averaged over the population. Clones whose ratio changed during the 
experiment by over 20 percent were inspected manually to verify that the source of 
change in pixel intensity distribution was nucleolar translocation.  
Finally, to quantify the extent and direction (nucleoli to nucleoplasm or vise versa) of the 
translocation, we calculated the ratio between mean fluorescence intensity of nucleoli vs. 
nucleoplasm (Rncll/nuc) at the two time points were the max/min ratio was maximized and 
minimized.  
For clarity in Fig. 3B and C, Rncll/nuc measurements (ranging from 0 to 3) were 
normalized to 0.5, 1 and 2 at the time of drug addition (t=0), based on the Rncll/nuc ratio at 
t=0; Rncll/nuc values <0.8 were normalized to 0.5, 0.8<Rncll/nuc <1.2 were normalized to 1 
and Rncll/nuc values >1.2 were normalized to 2. 
 
10. Determination of bimodal behavior 
The coefficient of variance (CV defined as the ratio between the std between cells and the 
mean) was measured for 400 proteins for 47 hours following addition of CPT (at a 20 
minute resolution) (see Supporting Fig. S15).All CVs were normalized to average 1 
(CV(i,j)/mean(mean(CV)) where i is protein number (i = 1..400) and j is time point 
(j=1..141) ). All proteins deviating 3 standard deviations from the average normalized CV 
were considered as bimodal candidates (N=53). Following manual inspection, 24 of these 
proteins listed in Supporting table 1 were classified as bimodal.  
 
11. Immunoblots against 20 selected proteins 
Total cell lysates were prepared with RIPA buffer (Pierce) according to manufacturer’s 
instructions. The protein concentrations were determined by BCA protein assay kit 
(Thermo scientific). Equal amounts of proteins were resolved on SDS-PAGE and 
subjected to immunoblot analysis by using the antibodies listed below. The intensity of 
protein bands was quantified by using ImageJ software. 
The following commercially available primary antibodies were used in the study: 
Antibodies against AKAP8L (ab51342), Calmodulin/CALM1 (ab38590), Cyclophilin 
A/PPIA (ab3563), DDX5 (ab21696), Enolase/ENO1 (ab35075 and ab49256), 
eIF3K/EIF3S12R (ab50736), GAPDH (ab9285 and ab9484), HSP90 (ab13492 and 
ab34909), Nucleophosmin/NPM1 (ab15440), PBX3 (ab56239), CKS2 (ab54658), 
Topoisomerase1 (ab28432) and VPS26 (ab23892) were purchased from Abcam. 
Antibodies against Calmodulin/CALM1 (FL-149), HDAC2 (H-54), Lamin A/C (H-110), 
RACK1/GNB2L (H-187 and B-3) and Fascin1/FAU (H-110) were obtained from Santa-
Cruz. 
Antibodies against RPL37 (A01), RPS7 (A01) and RPS3 (A01) proteins were obtained 
from Abnova. 
Anti-Myosin IIA/MYH9 (M8064) and anti-GFP (11814460001) antibodies were obtained 
from Sigma and Roche, respectively. 
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12. siRNA  
Dharmacon Accell SMARTpool E-003774-00-0050, Human DDX5, NM_004396, 
Dharmacon, was used. This pool contained 4 different siRNA sequences each of 19 base 
pairs. 
 
Target DDX5 sequence Molecular Weight 
(g/mol) 
Ext. Coeff  
(L/mol*cm) 
GCAUGUCGCUUGAAGUCUA 13,581.8 355,644 
CUCUUUAUAUUGUGUGUUA 13,543.2 377,716 
GCUGCACCUAUGAUUGGUU 13,575.3 349,948 
GCUCUAAGUGGAUUGGAUA 13,524.5 359,204 
 
Dharmacon, Accell siRNA was mixed with Accell delivery media supplemented with 3% 
FBS (fetal bovine serum) and 0.01% P/S (Penicillin, Streptomycin antibiotics). This mix 
was immediately added to the cells to a final concentration of 1µM of siRNA. For 12well 
format the mix included 1.562ml delivery media and 15.62µl siRNA. Cells were 
incubated for 72hours in normal condition of H1299 cells (37
o
C, 8% CO2). After 72hours 
medium was washed out and drug was added - 10µM of Camptothecin (CPT). siRNA 
efficiency was assessed by time-lapse fluorescence microscopy under incubated 
conditions (Figure S18) immediately after siRNA addition to the cells.  
Dharmacon Accell Non-targeting Pool (A-D-001910-10-50) was used as control 
following the same procedures as above. 
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Supporting text 
 
Limitations of library  
Details and limitations regarding library generation and expansion can be found at Sigal 
et al. Nature Protocols 2007 (4). In general, we used viral infection to introduce the YFP 
tag into the host cell. Viral integration sites are biased towards certain genes (hotspots) 
and to certain sites within genes, for example, the first intron. We observe an integration 
preference for specific gene functions and processes including RNA binding, ATPAse 
activity, splicing, translational elongation and ribosomal components (for details see S19 
and S20). Our experience has been that using different conditions for viral infection and 
sorting, saturation is still far off and that one can expect to cover a significant fraction of 
the proteome. The library has been constructed at the rate of about 50 
clones/person/month. Genes with only a single exon can not be captured.  It is likely that 
once recombination in human cells becomes feasible on a large scale, N and C-terminal 
tagging libraries will be developed, similar to those developed in yeast (14). Directed 
targeting can be used to enrich the library with proteins of interest that are currently not 
included.  
 
Comparison of response to Camptothecin vs. Irinotecan  
Campotothecin (CPT) has derivatives that are more commonly used in the clinic (i.e. 
topotecan, irinotecan and rubitecan). We asked how similar are dynamics observed with 
CPT to the dynamics with one of its derivatives – irinotecan (IT). To address this, we 
selected 10 representative proteins (chosen based on interesting dynamics following 
CPT) including: TOP1, TXNRD1, DDX5, RFC1, PFDN5, DNMT1, RPS3, CKS2, NCL 
and BAG2. We found that most of these proteins showed similarly shaped dynamic 
responses with CPT and IT (Fig. S12 and S13). In general, the amplitude was similar or 
milder for IT as compared to CPT at an equi-lethal dose. Out of four selected proteins 
that showed a bimodal response to CPT (BAG2, DDX5, RFC1 and RPS3), two showed 
bimodality in response to IT (DDX5 and RPS3). This suggests that the CPT derivative IT 
has similar qualitative protein dynamics to CPT, and also a few intriguing differences. 
 
On the possible identification of drug targets using dynamic proteomics approach 
Topoisomerase 1, the camptothecin target, is among the first to respond in a number of 
ways that involve dynamics of protein levels (among the first to degrade) and 
localizations (exit from nucleoli and fragmental exit from nucleus). Based on this 
observation one might suggest that this approach can help to identify targets of 
drugs/compounds with unknown targets. However, one may expect that some drugs will 
not lead to changes in the level or localization of their direct target. For example, 
proteosome inhibitors do not necessarily lead to changes in expression level of 
localization of proteosome components.  For such drugs, one may need to rely on 
secondary effects, for example, proteosome inhibitors may not change the level of the 
proteosome, but might affect the level of a range of proteosome targets. 
 
 
 
 
culum
e
Unknown Genes in LARC DB
All GO Cellular Components
Localization of 
uncharacterized proteins in 
the library
Localization of all known 
proteins
Localization of 
characterized proteins in 
library
Supplementary figure 1.  Tagged proteins in library are distributed across 
localizations similarly to the distribution of all known proteins. Distributions of protein 
localizations for A) All proteins in the library (LARC , Library of Annotated Reporter Clones) 
with published localization. B) Localization distribution of all proteins in the GO database. 
C) “Uncharacterized proteins in library based on manual inspection. (These proteins 
include hypothetical proteins and proteins encoded from regions in the genome denoted as 
ESTs and mRNA. These proteins have no published localization).
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Supplementary figure 2. Immunoblots for twenty proteins show dynamics highly 
similar to those in the library movies. A) For each protein: red line denotes 
quantification of immunoblot analysis with antibodies for each protein (measurements 
taken at: 0, 8.5, 17, 24,36, 40 and 45 hours following CPT addition (3-8 repeats). Blue line 
denotes the average fluorescence intensity dynamics for each of the proteins in response 
to CPT (measurements taken every 20 minutes for 47 hours). Average correlation 
between the two measurements across all proteins is R= 0.6. Error bars denote standard 
errors. 
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Supplementary figure 2 continued. B) Examples of immunoblots of four proteins which 
were quantified in (A). Graphs (blue lines) denote fluorescence measurements of tagged 
proteins from movies for ease of comparison.
B
Supplementary figure 3. The cell death dynamics measured by our algorithm is 
similar to neutral red based measurements . (A) The percent of cell death in response 
to CPT addition was computed by monitoring the number of individual cells that showed 
cell rounding followed by blebbing (a morphology characteristic of apoptotic cells) divided 
by the total number of cells. Measurements were done on thousands of cells with a 20 
minute time resolution. (B) Cell death in response to CPT was estimated using a neutral 
red (NR) assay which measures cell survival/viability (normalized  to the first time point at 
t=8hrs). Both assays show similar dynamics with a slow death rate in the first 35 hours 
followed by an increase in rate from 35 to 50h.
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Supplementary figure 4. Automatic detection of cell division events shows that 
cells stop dividing at 5h after drug addition. Plotted are tracks of total tagged protein 
(DDX5) intensity in individual cells. Blue asterisks denote mitosis events. Time is relative 
to the time of drug (CPT) addition. Note that protein levels drop two-fold with each 
division.
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Supplementary figure 5. Cell cycle stage at time of drug addition does not correlate 
with cell fate. Cells were tracked -20 hours prior drug addition until 48 hours after drug 
addition. Mitosis and cell death timing were automatically identified in over 300 movies 
taken in 7 different dates covering a wide range of clones. It was previously shown that the 
cell cycle of  H1299 cells used in this study is 18 +- 2.5 hours, and the relative fraction of 
time spent in G1, S and G2 cell cycle stages was determined by flow cytometry [Sigal et 
al. Nature Methods 2006]. We thus used the time of last mitosis prior to drug addition as 
an estimate  to the cell cycle stage at the time of drug addition. The y axis is the probability 
of cell survival. Standard error bars correspond to variability between movies. We do not 
find a statistically significant correlation between the cell cycle phase of an individual cell at 
drug addition and that cell’s probability to survive .
Supplementary figure 6.  Experiments on different days show highly repeatable 
dynamics. Each experiment was repeated between 2 to 8 times. Thin blue lines denote 
normalized total fluorescence averaged over many cells in one experiment, bold line 
denotes average over all days, error bars denote standard error. Mean error (std/mean) 
over all clones and all time points of all proteins is 0.13 (mean correlation between 
experiments at different dates  is R=0.8).
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Supplementary figure 6 continued. Individual cell data is reproducible between 
experiments performed on different days. A-C) Examples of three bimodal proteins DDX5, 
DKFZ434M1123 and RFC1. D-E) Examples of two non-bimodal proteins, GAPDH and 
LMNA.
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Supplementary figure 7.  Protein dynamics following CPT shows several types of 
profiles following CPT addition. Proteins are divided into five profiles of behavior as in 
Figure 2 in the main text. Each line is an average of at least 30 cells. Protein levels are 
normalized to initial protein levels as measured at the time the drug was added. Bold red 
line denotes mean profile of each cluster.
Supplementary figure 8. TOP1, the drug target shows degradation and dose 
dependent translocation, specific to CPT. A) Tagged TOP1 intensity decreases in  a 
CPT dose dependant manner. Each line denotes different concentration of CPT added at 
time 0 onto the cells. B) Tagged TOP1 exits from the nucleus to the cytoplasm in a CPT 
dose dependent manner (full lines). A control nuclear protein expressed in the same cells 
(XRCC5-mCherry) does not exit the nucleus at any of the CPT doses (dashed lines). 
Each line is the mean of all cells at each time-point. C) Fluorescence of tagged TOP1 
decreases to 65% of the initial fluorescence levels with half life of 1.5 hours. D) 
immunoblotting with anti-TOP1 and Anti-GFP shows fast decrease in endogenous and 
tagged TOP1 levels within 4 hours. Immunoataining with Anti-GFP Ab also reveals a 
degradation product of 40 kDa rising in anticorrelation with TOP1 degradation. E) Nuclear 
exit of tagged TOP1 does not occur with an equivalently lethal dose of etoposide, a 
topoisomerase-2 inhibitor drug. 
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Supplementary figure 9. Actinomycin-D causes nucleolar localization changes  
very similar to those caused by CPT (FIG 3 in main text). Localization changes of 
proteins in response to addition of 1μg/ml of Actinomycin-D (a transcription inhibitor). 
Time units in hours is relative to Actinomycin-D addition. Data was normalized to protein 
levels at time of addition (t=0). For clarity, normalized protein levels at time t=0 were 
shifted from 1, to values of 0.5, 1 and 2 according to the localization of the protein 
(nucleoli vs. the nucleoplasm). Proteins excluded from the nucleoli were denoted at t=0 
as 0.5, proteins equally dispersed were denoted as 1 and Proteins localized 
preferentially to the nucleoli were denoted 2. A) Tagged proteins that show a rapid 
decrease in nucleolar intensity. B) Tagged proteins that show a rapid increase in 
nucleolar/nucleoplasm ratio followed in some cases by a decrease back to basal levels. 
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Supplementary figure 10.  DNA damage protein RPA2 shows translocation to 
nuclear foci; other DNA damage related proteins show temporal changes in 
abundance. (A) Replication protein A2 (RPA2), localizes to nuclear foci upon CPT 
treatment, a well characterized response to DNA breaks. B) Average fluorescence over 
time following drug addition of 15 DNA damage related proteins, normalized to the initial 
protein levels at time zero. Blue denotes low and red denotes high. C) Localization of 
fluorescence for 13 DNA damage related proteins  proteins (nuclear intensity divided by 
total intensity, blue – nuclear, red - cytoplasmic) over time following drug addition. . 
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Supplementary figure 11.  Nuclear to cytoplasmic ratio of TXNRD1 
increases following CPT addition. Top panel: a fluorescent image of a cell 
with tagged TXNRD1. Time after drug (10 μM CPT) addition is indicated 
above each image (first image was taken before drug addition). Each line 
denotes the nuclear to cytoplasmic ratio measured for an individual  cell 
tracked over 50 hours. Bold green line denotes the average.
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Supplementary figure 12. TOP1 exists the nucleoli upon irinotecan treatment, with 
dynamics similar to CPT but lower amplitude. Nucleoli exit was measured by dividing 
the top 10% pixels by the bottom 10% pixels within the nucleus. TOP1 exits the nucleoli at 
dose dependent rates, with larger effects of CPT as compared to irinotecan. 
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Supplementary figure 13. Protein dynamics and localization changes upon treatment with 
irinotrecan are similar to those observed with CPT. (A) Comparison of translocation dynamics  
between nucleoli and nucleoplasm in response to Irinotecan (250 μM) and CPT (10 μM). Shown 
are 4 proteins, DDX5 (DEAD box protein 5), TOP1 (Topoisomerase 1), NCL (Nucleolin) and 
DNMT1 (DNA methylase 1). (B) Comparison of translocation dynamics  between nucleus and 
cytoplasm for three proteins PFDN5 (Prefoldin 5), TOP1 (Topoisomerase 1)and TXNRD1 
(thioredoxin reductase 1). (C) Comaprison of bimodality for four proteins, DDX5 (DEAD box protein 
5), BAG2 (BCL2-associated athanogene 2 ), RFC1 (replication factor C large subunit) and RPS3 
(ribosomal protein small subunit 3). 
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Supplementary Figure 14. Protein dynamics upon treatment with etoposide
(5μM) differ from those observed with CPT (10 μM). Shown are four proteins: 
Myosin heavy chain 9 (MYH9), Calponin 3 (CNN3), defender against the death 1 
(DAD1) and the splicing associated factor YT521. CPT average profile in blue and 
etoposide average profile in red.
DAD1
Supplementary figure 15.  Cell-cell variability of most proteins rises slightly after 
drug, and rises sharply at 25h for a subset of proteins. Each line denotes CV of a 
different protein (total 400 proteins shown), where CV is the Coefficient of variance 
(std/mean of cells in the clone at each time point). In red: proteins that show CV of over 3 
standard deviations from the average normalized CV of all proteins. Average CV of all 400 
proteins is bold black and that of the 53 ‘bimodal’ proteins is bold brown.
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Supplementary figure 16.  DDX5 shows different dynamics in response to different 
drugs.  Response of DDX5 to Cis-Platinum 25μM and Etoposide 40μM. Each line 
denotes total fluorescence measured for a single cell. 
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Supplementary figure 17.  RFC1 - a bimodal protein that correlates with cell fate, 
and an example of a bimodal protein that does not. A) Replication factor RFC1 
shows an increase in intensity in cells that survive the drug after 48h, and a decrease in 
cells that show the morphological changes associated with cell death. Heavy colored 
lines are cells that die, with darker colors corresponding to earlier cell death. Blue lines 
are cells that do not die in the movie. B) Cells that show the morphological correlates of 
cell death have significantly higher slopes of RFC1 fluorescence accumulation than 
cells that do not (T-test P<10-6). Slopes are defined as in Fig. 4 of the main text. C-D) 
The hypothetical protein DKFZp434M1123 shows similar dynamics to DDX5, (coloring 
as described in A. However, no significant correlation is found between the dynamics 
and cell fate (T-test P=0.18).
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Supplementary figure 18.  Reduction in DDX5 levels following siRNA addition. A) 
Average fluorescence levels of DDX5 with DDX5-RNAi (blue line), without DDX5-RNAi 
(green line) and of the cherry tag following DDX5-RNAi (red line). Data was normalized 
to first time point. B-D) Single cell data, from which averages were calculated on. B) 
data of tagged DDX5 with OUT DDX5-RNAi, C) data of cherry tag following DDX5-RNAi, 
D) data of tagged DDX5 following DDX5-RNAi.
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P-value color scale
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10-7 to 10-
9  >10-9
Description P-value Enrichment
RNA binding 5.73E-35 3.61
ATPase activity 1.55E-27 4.68
hydrolase activity, acting on acid anhydrides, in 
phosphorus-containing anhydrides 2.57E-26 3.43
hydrolase activity, acting on acid anhydrides 3.42E-26 3.42
pyrophosphatase activity 7.26E-26 3.41
structural constituent of ribosome 1.01E-25 5.73
nucleoside-triphosphatase activity 2.22E-25 3.45
ATPase activity, coupled to transmembrane
movement of substances 1.63E-19 6.43
ATPase activity, coupled to movement of 
substances 2.29E-19 6.37
hydrolase activity, acting on acid anhydrides, 
catalyzing transmembrane movement of 
substances 3.20E-19 6.31
primary active transmembrane transporter 
activity 6.46E-19 6
P-P-bond-hydrolysis-driven transmembrane
transporter activity 6.46E-19 6
protein binding 1.19E-18 1.37
ATPase activity, coupled 3.34E-18 4.17
structural molecule activity 1.85E-16 2.62
nucleotide binding 3.58E-15 1.8
actin binding 1.59E-12 3.22
binding 5.33E-12 1.15
cytoskeletal protein binding 2.83E-11 2.66
ATP binding 8.86E-10 1.78
Figure S19: Viral integration is bias to genes that are involved in specific 
functions and processes. See next figure for description.
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Description P-value Enrichment
translational elongation 4.37E-38 10.12
RNA splicing 2.50E-12 3.4
mRNA metabolic process 4.62E-11 3.02
RNA splicing, via transesterification reactions 
with bulged adenosine as nucleophile 1.26E-10 4.55
RNA splicing, via transesterification reactions 1.26E-10 4.55
nuclear mRNA splicing, via spliceosome 1.26E-10 4.55
mRNA processing 5.81E-10 3.02
Figure S20: Viral integration is bias to genes that are involved in specific functions 
and processes. Viral integration preference was measured by computing the hyper
geometric GO enrichment of  genes in our library compared to all human genes. Several 
function and processes are highly enriched (P < 10-9) including RNA binding, ATPAse
activity, splicing, translational elongation and ribosomal components. Images generated by 
the Gorilla software (http://cbl-gorilla.cs.technion.ac.il/).
 
Supporting tables 
 
Supporting Table 1: Proteins tagged with YFP are full length fusions. Comparison 
between observed size of YFP-fused protein and expected size for 23 proteins that 
showed a detectable band when immunoblotted with anti-GFP. 
 
Size of YPF-fused protein  (kDa) Protein name Clone ID 
Expected Observed 
CALM1 150506pl1E2 ~47 (20+27) ~47 
CKS2 010806pl4A1 ~47 (10+27) ~48 
090505pl3D6 DDX5 
010806pl2F1 
~95 (68+27) ~95 
041206pl1C1 ~55 EIF3S12 
041206pl5H5 
~55 (28+27) 
~57 
ENO1 150506pl2F1 ~77(50+27) ~77 
FAU 170407pl2A5 ~41 (14+27) ~45 
FSCN1 010806pl1E12 ~82 (55+27) ~85 
GAPDH 310806pl2C2 67 (40+27) ~66 
GNB2L1 310806pl1H12 ~64 (37+27) ~66 
HDAC2 041206pl1E4 ~87 (60+27) ~87 
HSP90AA1 310506pl1B9 ~120 (90+27) ~120 
Lamin A: ~96 
(69+27) 
~96 LMNA/C 310806pl1H11 
Lamin C: ~89 
(62+27) 
~89 
MYH9 010506pl1C12 ~227 (200+27) ~227 
NPM1 010806pl2H1 ~60 (33+27) ~67 
PBX3 041206pl3C8 ~67 (40+27) ~70 
010806pl2B4 PEPP-2 
010806pl2D11 
~59 (32+27) ~58 
310506pl4C1 ~49 PPIA 
031206pl3B6 
~47 (20+27) 
~47 
RPL18 150506pl1C8 ~47 (20+27) ~ 47 
RPS3A 150506pl1B7 ~63 (36+27) ~66 
RPS7 310506pl1G12 ~54 (27+27) ~54 
TJP1 050707pl1C9 ~227 (200+27) ~227 
200906pl1C12 TOP1 
200306pl1H1 
~117(90+27) ~120 
010506pl1B1 
050707pl1B11 
  
VPS26A 
  
211007pl2A8 
  
~67 (40+27) 
  
  
~70 
  
 
 
 
Supporting Table 2: List of proteins that changed localization in response to drug 
 
 
Protein name Clone ID Description Response to CPT 
TOP1 200906pl1C12 topoisomerase 1 Rapid decrease in nucleoli 
followed by decrease in nucleus 
NCL 160507pl3D6 nucleolin Rapid decrease in nucleoli 
DNMT1 310806pl2C3 DNA methylase 1 Rapid decrease in nucleoli 
ARID1B 041206pl7B1 AT rich interactive domain 1B Rapid decrease in nucleoli 
RPL39 200906pl2H12 Ribosomal protein large 
subunit 39 
Rapid decrease in nucleoli 
FAU 170407pl2A5 fusion protein consisting of the 
ubiquitin-like protein fubi at 
the N terminus and ribosomal 
protein S30 at the C terminus 
Rapid decrease in nucleoli 
UPF3 041206pl6A3 UPF3 regulator of nonsense 
transcripts homolog A 
Rapid increase in nucleoli 
followed by nucleolar decrease  
DDX5 010806pl2F1 RNA helicase p68 Rapid increase in nucleoli 
followed by nucleolar decrease 
C3ORF19 010506pl1E8 hypothetical protein Rapid increase in nucleoli 
followed by nucleolar decrease 
LPIN2 170407pl1B6 lipin 2 Rapid increase in nucleoli 
followed by nucleolar decrease 
PFDN5 160507pl1E3 prefoldin subunit 5 (c-myc 
binding protein) 
Rapid nuclear decrease 
followed by nuclear increase  
TXNRD1 010506pl1E8 thioredoxin reductase 1 Slow nuclear increase 
TXN 160507pl1B6 thioredoxin Slow nuclear increase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supporting Table 3: List of proteins showing bimodal behavior 
 
Protein name Clone ID description 
Reference to 
association of 
protein with cell 
death 
ARL3 050707pl3G1 ADP-ribosylation factor-like 3  
BAG2 010806pl1C7 BCL2-associated athanogene 2  
BAG3 170407pl3D4 BCL2-associated athanogene 3 (15) 
C9ORF40 130207pl1E1 hypothetical protein LOC55071  
CALM1 150506pl1E2 calmodulin 1 (16, 17) 
CAV1 170407pl1C2 caveolin 1 (18) 
CCDC23 310506pl2C3 coiled-coil domain containing 23  
DDX5 010806pl2F1 p68 RNA helicase (19) 
DKFZP434M1123 160507pl1B11 hypothetical protein  
EIF1AX 010806pl2B11 
eukaryotic translation initiation factor 
1A, X-linked 
 
FABP5 200906pl1B6 fatty acid binding protein 5  
FSCN1 010806pl1E12 
fascin homolog 1, actin-bundling 
protein 
 
PCMTD2 010506pl2D2 
protein-L-isoaspartate (D-aspartate) 
O-methyltransferase domain 
containing 
 
PDCD5 170407pl1B5 programmed cell death 5  
PFN1 050707pl2E5 profilin 1  
NPM1 010806pl2H1 Nucleophosmin (B23) (20) 
PPP1R2 010806pl1G5 
protein phosphatase 1, regulatory 
(inhibitor) subunit 2 
 
PTTG1 310506pl2C2 pituitary tumor-transforming 1  
RFC1 050707pl1B12 replication factor C (activator 1)  
RPS3 150506pl2B7 ribosomal protein S3 (21) 
SLBP 010506pl2E6 stem-loop binding protein (22) 
SPCS1 050707pl2F4 
signal peptidase complex subunit 1 
homolog 
 
TOMM70A 170407pl3H11 
translocase of outer mitochondrial 
membrane 70 homolog A 
 
YT521 010806pl1F2 YTH domain containing 1  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supporting Table 4: List of Expressed Sequence Tags (ESTs) and hypothetical 
proteins and their measured localizations. For each entry (EST or hypothetical protein) 
we measured the ratio of total fluorescence in the cytoplasm vs. total fluorescence in the 
whole cell, above or equal to 0.5 is denoted as nuclear localization and below 0.5 as 
cytoplasmic localization. 
 
  names Cytoplasm / whole cell Nucleus Cytoplasm 
1 AA282714 0.7866 0 1 
2 AA479512 0.779 0 1 
3 AA843465 0.3618 1 0 
4 AA928516 0.4001 1 0 
5 AF086125 0.8349 0 1 
6 AF087973 0.7233 0 1 
7 AI027434 0.2965 1 0 
8 AI208228 0.7128 0 1 
9 AI434862 0.7284 0 1 
10 AI671392 0.3552 1 0 
11 AI733141 0.5479 0 1 
12 AI801879 0.2595 1 0 
13 AI870477 0.7639 0 1 
14 AK022356 0.6871 0 1 
15 AK023312 0.7707 0 1 
16 AK023856 0.2276 1 0 
17 AK024998 0.6494 0 1 
18 AK057505 0.8767 0 1 
19 AK091021 0.7426 0 1 
20 AK091830 0.6938 0 1 
21 AK092541 0.691 0 1 
22 AK092875 0.3468 1 0 
23 AK095109 0.7859 0 1 
24 AK097658 0.3469 1 0 
25 AK098306 0.6876 0 1 
26 AK124927 0.1741 1 0 
27 AK127572 0.5898 0 1 
28 AK127877 0.7119 0 1 
29 AK130903 0.7623 0 1 
30 AK131516 0.8201 0 1 
31 AV741821 0.7017 0 1 
32 AW070221 0.6662 0 1 
33 AW592040 0.8192 0 1 
34 AW662723 0.623 0 1 
35 AY054401 0.7634 0 1 
36 AY176665 0.7225 0 1 
37 BC033363 0.8908 0 1 
38 BC034424 0.6379 0 1 
39 BC035195 0.6273 0 1 
40 BC035377 0.4531 1 0 
 
41 BC038752 0.7525 0 1 
42 BC039104 0.8318 0 1 
43 BC040610 0.7936 0 1 
44 BC042060 0.7563 0 1 
45 BC042816 0.7201 0 1 
46 BC042855 0.8326 0 1 
47 BC043574 0.685 0 1 
48 BC044257 0.6643 0 1 
49 BC044741 0.3626 1 0 
50 BC053955 0.6361 0 1 
51 BC054862 0.8227 0 1 
52 BC078172 0.8116 0 1 
53 BC108263 0.8339 0 1 
54 BC127846 0.8948 0 1 
55 BE745782 0.2625 1 0 
56 BE785612 0.7293 0 1 
57 BE044435 0.7093 0 1 
58 BF062994 0.714 0 1 
59 BF245041 0.7327 0 1 
60 BF594738 0.2631 1 0 
61 BF688062 0.2489 1 0 
62 BG189068 0.6341 0 1 
63 BG201613 0.194 1 0 
64 BG203790 0.2773 1 0 
65 BI462136 0.3108 1 0 
66 BI559775 0.727 0 1 
67 BI825982 0.7214 0 1 
68 BM461531 0.4477 1 0 
69 BM690995 0.7291 0 1 
70 BQ184944 0.7141 0 1 
71 BQ233546 0.6304 0 1 
72 BU533525 0.6682 0 1 
73 BU534173 0.303 1 0 
74 BU619815 0.3354 1 0 
75 BX089034 0.8095 0 1 
76 BX090666 0.7584 0 1 
77 BX100329 0.7407 0 1 
78 BX100818 0.7962 0 1 
79 BX103408 0.3196 1 0 
80 BX103636 0.8348 0 1 
81 BX104605 0.7985 0 1 
82 BX537644 0.7389 0 1 
83 BX537772 0.8385 0 1 
84 BX648555 0.6607 0 1 
85 BX648926 0.3742 1 0 
86 C12ORF43 0.3436 1 0 
87 C12ORF45 0.3186 1 0 
 
88 C14ORF112 0.4427 1 0 
89 C14ORF2 0.7418 0 1 
90 C16ORF14 0.4108 1 0 
91 C19ORF33 0.622 0 1 
92 C19ORF43 0.4308 1 0 
93 C19ORF53 0.7672 0 1 
94 C19ORF61 0.7063 0 1 
95 C20ORF24 0.7255 0 1 
96 C21ORF59 0.7483 0 1 
97 C2ORF25 0.7598 0 1 
98 C3ORF19 0.3994 1 0 
99 C3ORF6 0.7952 0 1 
100 C7ORF48 0.787 0 1 
101 C8ORF44 0.4354 1 0 
102 C9ORF40 0.7684 0 1 
103 CB045860 0.724 0 1 
104 CD692919 0.6126 0 1 
105 CN267986 0.6675 0 1 
106 CN280387 0.7509 0 1 
107 CN398253 0.7986 0 1 
108 CR593740 0.7132 0 1 
109 CR604408 0.8164 0 1 
110 CR623475 0.6816 0 1 
111 CR626360 0.7563 0 1 
112 CR627148 0.7868 0 1 
113 CR737784 0.8232 0 1 
114 CR994463 0.659 0 1 
115 DB049861 0.8422 0 1 
116 DB054822 0.7785 0 1 
117 DB186251 0.2773 1 0 
118 DB331110 0.2272 1 0 
119 DB514539 0.7233 0 1 
120 DB522524 0.7956 0 1 
121 DC347972 0.6791 0 1 
122 DKFZP434M1123 0.8034 0 1 
123 EF565105 0.5012 0 1 
124 ESTDB089792 0.7495 0 1 
125 FLJ10154 0.3163 1 0 
126 FLJ10292 0.7617 0 1 
127 FLJ20105 0.8155 0 1 
128 FLJ31951 0.8475 0 1 
129 FLJ32065 0.4847 1 0 
130 FLJ35776 0.752 0 1 
131 KIAA1064 0.1932 1 0 
132 KIAA1430 0.3263 1 0 
133 LOC130074 0.6583 0 1 
134 LOC284184 0.6882 0 1 
 
135 LOC286016 0.7608 0 1 
136 LOC441161 0.6789 0 1 
137 LOC541471 0.6685 0 1 
138 MGC16824 0.7113 0 1 
139 MGC5509 0.7338 0 1 
140 MGC71993 0.5969 0 1 
141 MRNA-AK098520 0.2283 1 0 
142 NM_001093732 0.6534 0 1 
143 NM_015681 0.6197 0 1 
144 T85821 0.7951 0 1 
145 T85822 0.7259 0 1 
146 T85823 0.815 0 1 
147 T85824 0.8146 0 1 
148 AI342698 0.6337 0 1 
149 AK094352 0.6052 0 1 
150 AK094903 0.3903 1 0 
151 AK128457 0.3942 1 0 
152 AW418496 0.4929 1 0 
153 AX748230 0.7376 0 1 
154 BC005233 0.5561 0 1 
155 BC036259 0.6996 0 1 
156 BG221753 0.6439 0 1 
157 BX648475 0.795 0 1 
158 C12ORF48 0.3315 1 0 
159 C14ORF166 0.6383 0 1 
160 C6ORF106 0.5592 0 1 
161 C7ORF11 0.4211 1 0 
162 LOC729416 0.7143 0 1 
163 N68399 0.6699 0 1 
164 NT_022171 0.6871 0 1 
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Supporting movies 
 
Supporting Movie 1:  
Time-lapse movie of transmitted light images of the clone with YFP CD-tagged DDX5. 
Movie duration is 72 hours, 24 hours before drug addition followed by 48 hours after 
drug addition (time-lapse: 1 frame per 20 minutes). 
 
Supporting Movie 2: 
Time-lapse movie of yellow fluorescence images of the clone with YFP CD-tagged 
DDX5. Movie duration is 72 hours, 24 hours before drug addition followed by 48 hours 
after drug addition (time-lapse: 1 frame per 20 minutes). 
 
Supporting Movie 3: 
Time-lapse movie of red fluorescence images of the clone with YFP CD-tagged DDX5. 
Movie duration is 72 hours, 24 hours before drug addition followed by 48 hours after 
drug addition (time-lapse: 1 frame per 20 minutes). 
 
Supporting Movie 4: 
Time-lapse movie of segmentation and tracking of the clone with YFP CD-tagged 
DDX5. Movie duration is 72 hours, 24 hours before drug addition followed by 48 hours 
after drug addition (time-lapse: 1 frame per 20 minutes). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
